Park Seong-Hyun, Park Ki-Su, Kang Dong-Hun, Hwang Jeong-Hyun, Hwang Sung-Kyoo
Department of Neurosurgery, Kyungpook National University Hospital, Daegu, South Korea.
Department of Neurosurgery, Kyungpook National University Hospital, Daegu, South Korea.
World Neurosurg. 2017 Oct;106:836-843. doi: 10.1016/j.wneu.2017.04.143. Epub 2017 May 2.
We reviewed our 7-year experience to assess the efficacy of stereotactic radiosurgery (SRS) for dural carotid cavernous fistulas (DCCFs). We analyzed the clinical outcome, complications, and angiographic results.
We performed a retrospective analysis of 18 consecutive patients with DCCFs treated by SRS alone using Gamma Knife between 2009 and 2015. Median target volume was 2.6 cm (range, 0.6-11.6 cm), and median radiation dose to the target was 17 Gy (range, 14-19 Gy). Median follow-up period was 30 months (range, 6-65 months).
Fifteen patients (83%) achieved total obliteration of the DCCF, and a subtotal obliteration of the DCCF was achieved in 3 patients (17%). Total obliteration rates after SRS were 53% at 1 year and 90% at 2 years. Twelve patients (67%) showed complete recovery from symptoms or signs, and 6 patients (33%) showed incomplete recovery. Improvement rates of neurologic function after SRS were 56% at 1 month, 72% at 3 months, and 94% at 6 months. None of the patients experienced radiation-related complications. A univariate analysis revealed that absence of hypertension (P = 0.025), seizure (P = 0.025), and cortical venous drainage (P = 0.013) were significantly associated with symptoms improvement.
SRS for DCCFs offered a high obliteration rate with low risk of radiation-induced complications. In patients with benign DCCFs that are not amenable to embolization or microsurgery, SRS is a safe and effective treatment for complete obliteration of the arteriovenous shunt and for improving quality of life.
我们回顾了7年的经验,以评估立体定向放射外科(SRS)治疗硬脑膜型颈内动脉海绵窦瘘(DCCF)的疗效。我们分析了临床结果、并发症及血管造影结果。
我们对2009年至2015年间连续18例仅接受伽玛刀SRS治疗的DCCF患者进行了回顾性分析。中位靶体积为2.6 cm(范围0.6 - 11.6 cm),靶区中位放射剂量为17 Gy(范围14 - 19 Gy)。中位随访期为30个月(范围6 - 65个月)。
15例患者(83%)实现了DCCF的完全闭塞,3例患者(17%)实现了DCCF的部分闭塞。SRS后1年完全闭塞率为53%,2年为90%。12例患者(67%)症状或体征完全恢复,6例患者(33%)恢复不完全。SRS后1个月神经功能改善率为未56%,3个月为72%,6个月为94%。所有患者均未发生与放射相关的并发症。单因素分析显示,无高血压(P = 0.025)、癫痫(P = 0.025)和皮质静脉引流(P = 0.013)与症状改善显著相关。
SRS治疗DCCF闭塞率高,放射诱发并发症风险低。对于不宜行栓塞或显微手术的良性DCCF患者,SRS是完全闭塞动静脉分流及改善生活质量的一种安全有效的治疗方法。